New Directions in Antiplatelet Therapy

摘要: Atherosclerosis is a chronic inflammatory process that known to be the underlying cause of coronary artery disease (CAD).1 In addition being first step primary hemostasis, platelets play pivotal role in thrombotic follows rupture, fissure, or erosion an atherosclerotic plaque.2 Because atherothrombotic events are essentially platelet-driven processes, this underscores importance antiplatelet agents, which represent cornerstone treatment, particularly settings patients with acute syndromes (ACS) and undergoing percutaneous intervention (PCI). Currently, there 3 different classes drugs approved for clinical use recommended per guidelines treatment prevention ischemic ACS PCI: (1) cycloxigenase-1 (COX-1) inhibitor: aspirin, (2) adenosine diphosphate (ADP) P2Y12 receptor antagonists: ticlopidine, clopidogrel, prasugrel, ticagrelor, (3) glycoprotein IIb/IIIa inhibitors (GPI): abciximab, eptifibatide, tirofiban.3–6 GPIs currently available only parenteral administration, therefore their limited phase PCI. Oral namely aspirin inhibitors, both long-term phases treatment. For over decade, dual therapy (DAPT) clopidogrel has been considered standard care setting However, considerable number adverse continue occur DAPT regimen, led development newer more potent agents. The objective present manuscript provide overview on most recent advances agents PCI, as well emerging (Figure 1). Other …